Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent share price underperformance is overdone and offers an attractive entry point ahead of several catalysts in 2025, the analysts tell investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Can Telehealth Frontrunner Hims & Hers Health Bounce Back from its Q4 Bombshell?
- Novo Nordisk Announces 2025 Annual General Meeting Details
- Novo Nordisk: Strong Market Position and Growth Potential with Focus on Wegovy and Ozempic Strategies
- Shortage of Novo Nordisk’s (NVO) Weight Loss Drugs Is Resolved, Says FDA
- Why Is HIMS Stock Dropping Today?